Cocaine embryofetopathy

Cocaine embryofetopathy (also known as fetal cocaine syndrome or cocaine embryopathy) is a condition resulting from prenatal exposure to cocaine during pregnancy. Cocaine crosses the placenta and affects the developing fetus through its potent vasoconstrictive properties, which reduce blood flow to the placenta and fetal organs, as well as through direct neurotoxic effects. This is not a genetic disorder but rather a teratogenic condition caused by maternal cocaine use during gestation. The condition can affect multiple body systems. Key clinical features include intrauterine growth restriction, microcephaly, and various congenital malformations. Affected infants may present with craniofacial abnormalities, limb defects (including limb reduction defects), genitourinary malformations, and cardiovascular anomalies. Neurological consequences are prominent and may include neurobehavioral disturbances, irritability, feeding difficulties, abnormal sleep patterns, and long-term neurodevelopmental delays. Intestinal atresia and other gastrointestinal anomalies have also been reported, likely related to vascular disruption during fetal development. There is no specific cure or targeted treatment for cocaine embryofetopathy. Management is supportive and multidisciplinary, focusing on addressing individual symptoms and developmental needs. This may include early intervention programs, developmental therapies (speech, occupational, and physical therapy), nutritional support, and management of any structural anomalies, which may require surgical correction. Long-term neurodevelopmental follow-up is essential, as affected children may experience learning difficulties, attention problems, and behavioral challenges. Prevention through maternal abstinence from cocaine during pregnancy remains the most important strategy.

Common questions about Cocaine embryofetopathy